New drug treatments for ocular allergies

References

• Key B. Allergy and allergic diseases. Part I. N. Engl. J. Med.344, 30–37 (2001).
   PubMedGoogle Scholar
• Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J. Allergy Clin. Immunol.115, 118–122 (2005).
   PubMed Web of Science ®Google Scholar
• Leonardi A. Emerging drugs for ocular allergy. Expert Opin. Emerg. Drugs10, 505–520 (2005).
   PubMedGoogle Scholar
• Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog. Ret. Eye Res.21, 319–339 (2002).
   PubMed Web of Science ®Google Scholar
• Blepharitis and Conjunctivitis. Guidelines for Diagnosis and treatment. BenEzra D (Ed.). Editorial Glosa, Barcelona, Spain (2006).
   Google Scholar
• Wilson FM. Allergy to topical medication. Int. Ophthalm. Clin.43, 73–81 (2003).
   PubMedGoogle Scholar
• Motterle L, Diebold Y, Enriquez de Salamanca A et al. Altered expression of neurotransmitter receptors and neuromediators in vernal keratoconjunctivitis. Arch. Ophthalmol.124(4), 462–468 (2006).
   PubMedGoogle Scholar
• Kumagai N, Fukuda K, Fujitsu Y, Yamamoto K, Nishida T. Role of structural cells of the cornea and conjunctiva in the pathogenesis of vernal keratoconjunctivitis. Prog. Retin. Eye Res.25(2), 165–187 (2006).
   PubMed Web of Science ®Google Scholar
• Uchio E, Ono SY, Ikezawa Z, Ohno S. Tear levels of interferon-γ, interleukin (IL)-2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. Clin. Exp. Allergy30(1), 103–109 (2000).
   PubMed Web of Science ®Google Scholar
• Calder VL, Jolly G, Hingorani M et al. Cytokine production and mRNA expression by conjunctival T cell lines in chronic allergic eye diseases. Clin. Exp. Allergy29(9), 1214–1222 (1999).
   PubMed Web of Science ®Google Scholar
• Miyazaki D, Nakamura T, Toda M, Cheung-Chau KW, Richardson RM, Ono SJ. Macrophage inflammatory protein-1α as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions. J. Clin. Invest.115(2), 434–442 (2005).
   PubMed Web of Science ®Google Scholar
• Anderson DF, Zhang S, Bradding P et al. The relative contribution of mast cell subsets to conjunctival T(H)2-like cytokines. Invest. Ophthalmol. Vis. Sci.42(5), 995–1001 (2001).
   PubMed Web of Science ®Google Scholar
• Cook EB, Stahl JL, Barney NP, Graziano FM. Mechanisms of antihistamines and mast cell stabilizers in ocular allergic inflammation. Curr. Drug Targets Inflamm. Allergy1(2), 167–180 (2002).
   PubMedGoogle Scholar
• Leonardi A. Role of histamine in allergic conjunctivitis. Acta Ophthalmol. Scand.230(Suppl.), 18–21 (2000).
   Google Scholar
• Bielory L, Ghafoor S. Histamine receptors and the conjunctiva. Curr. Opin. Allergy Clin. Immunol.5(5), 437–440 (2005).
   PubMed Web of Science ®Google Scholar
• Tanaka S, Ichikawa A. Recent advances in molecular pharmacology of the histamine systems: immune regulatory roles of histamine produced by leukocytes. J. Pharmacol. Sci.101, 19–23 (2006).
   PubMed Web of Science ®Google Scholar
• Mans BJ. Tick histamine-binding proteins and related lipocalins: potential as therapeutic agents. Curr. Opin. Investig. Drugs6(11), 1131–1135 (2005).
   PubMedGoogle Scholar
• Abu El-Asrar AM, Struyf S, Van Damme J, Geboes K. Role of chemokines in vernal keratoconjunctivitis. Int. Ophthalmol. Clin.43, 33–39 (2003).
   PubMedGoogle Scholar
• Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin. Exp. Allergy36, 777–784 (2006).
   PubMed Web of Science ®Google Scholar
• Leonardi A, Jose P, Zhan, Calder V. Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology110, 487–492 (2003).
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ohbayashi M, Toda M, Hall DA, Horgan CM, Ono SJ. A specific CCR3 chemokine receptor antagonist inhibits both early and late phase allergic inflammation in the conjunctiva. Immunol. Res.33(3), 213–221 (2005).
   PubMed Web of Science ®Google Scholar
• Metz DP, Bacon AS, Holgate S, Lightman SL. Phenotypic characterization of T cells infiltrating the conjunctiva in chronic allergic eye disease. J. Allergy Clin. Immunol.98, 686–696 (1996).
   PubMed Web of Science ®Google Scholar
• Montan PG, Scheynius A, van der Ploeg I. Similar T helper Th2-like cytokine mRNA expression in vernal keratoconjunctivitis regardless of atopic constitution. Allergy57, 436–441 (2002).
   PubMed Web of Science ®Google Scholar
• Leonardi A, Fregona IA, Plebani M, Secchi AG, Calder VL. Th1- and Th2-type cytokines in chronic ocular allergy. Graefes Arch. Clin. Exp. Ophthalmol.244(10), 1240–1245 (2006).
   PubMedGoogle Scholar
• Jutel M, Akdis M, Blaser K, Akdis CA. Mechanisms of allergen specific immunotherapy. T-cell tolerance and more. Allergy61(7), 796–807 (2006).
   PubMed Web of Science ®Google Scholar
• Leonardi A, Brun P, Abatangelo G, Plebani M, Secchi AG. Tear levels and activity of matrix metalloproteinase (MMP)-1 and MMP-9 in vernal keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci.44, 3052–3058 (2003).
   PubMed Web of Science ®Google Scholar
• Leonardi A, Brun P, Sartori MT et al. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci.46, 1364–1370 (2005).
   PubMed Web of Science ®Google Scholar
• Ghavami S, Hashemi M, de Serres FJ, Naghibzadeh Bajestani S, Mehrabifar H, Leonardi A. Trypsin inhibitory capacity in vernal keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci.48(1), 264–269 (2007).
   PubMedGoogle Scholar
• Miyazaki D, Liu G, Clark L, Ono SJ. Prevention of acute allergic conjunctivitis and late-phase inflammation with immunostimulatory DNA sequences. Invest. Ophthalmol. Vis. Sci.41(12), 3850–3855 (2000).
   PubMed Web of Science ®Google Scholar
• Fukushima A, Ozaki A, Jian Z et al. Dissection of antigen-specific humoral and cellular immune responses for the development of experimental immune-mediated blepharoconjunctivitis in C57BL/6 mice. Curr. Eye Res.30(4), 241–248 (2005).
   PubMed Web of Science ®Google Scholar
• Fukushima A, Yamaguchi T, Ishida W, Fukata K, Yagita H, Ueno H. Roles of OX40 in the development of murine experimental allergic conjunctivitis: exacerbation and attenuation by stimulation and blocking of OX40. Invest. Ophthalmol. Vis. Sci.47(2), 657–663 (2006).
   PubMedGoogle Scholar
• Fukushima A, Yamaguchi T, Ishida W et al. Engagement of 4–1BB inhibits the development of experimental allergic conjunctivitis in mice. J. Immunol.175(8), 4897–4903 (2005).
   PubMed Web of Science ®Google Scholar
• Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs65, 215–228 (2005).
   PubMed Web of Science ®Google Scholar
• Secchi A, Ciprandi G, Leonardi A et al. Safety and efficacy comparison of emedastine 0.05% ophthalmic solution compared to levocabastine 0.05% ophthalmic suspension in pediatric subjects with allergic conjunctivitis. Acta Ophthalmol. Scand.78(230), 42–47 (2000).
   PubMedGoogle Scholar
• Yanni JM, Miller ST, Gamache DA, Spellman JM, Xu S, Sharif NA. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann. Allergy Asthma Immunol.79, 541–545 (1997).
   PubMed Web of Science ®Google Scholar
• Leonardi A, Borghesan F, Avarello A, Plebani M, Secchi AG. Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis. Br. J. Ophthalmol.81, 23–26 (1997).
   PubMed Web of Science ®Google Scholar
• Santos CI, Huang AJ, Abelson MB et al. Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis. Am. J. Ophthamol.117, 488–497 (1994).
   PubMed Web of Science ®Google Scholar
• Abelson MB, Berdy GJ, Mundorf T, Amdahl LD, Graves AL. Pemirolast study group. Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, Phase III studies. J. Ocul. Pharmacol. Ther.18, 475–488 (2002).
   PubMed Web of Science ®Google Scholar
• Bouhlal H, Blondin C, Haeffner-Cavaillon N, Goldschmidt P. N acetyl-aspartyl glutamic acid (NAAGA) inhibits the adhesion of leukocytes to activated endothelial cells and down-modulates the cytokine-induced expression of adhesion molecules. J. Fr. Ophtalmol.25, 993–1000 (2002).
   PubMedGoogle Scholar
• Dell SJ, Lowry GM, Northcutt JA et al. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J. Allergy Clin. Immunol.102, 251–255 (1998).
   PubMed Web of Science ®Google Scholar
• Leonardi A, Papa V, Milazzo G, Secchi AG. Efficacy and safety of desonide phosphate for the treatment of allergic conjunctivitis. Cornea21, 476–481 (2002).
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Buscaglia S, Catrullo A et al. Azelastine eye drops reduce and preventallergic conjunctival reaction and exert anti-allergic activity. Clin. Exp. Allergy27, 182–191 (1997).
   PubMed Web of Science ®Google Scholar
• Chand N, Pillar J, Diamantis W, Sofia RD. Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs. Agents Actions16(5), 318–322 (1985).
   PubMedGoogle Scholar
• Lytinas M, Kempuraj D, Huang M et al. Azelastine’s inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine. Allergy Asthma Proc.23(1), 45–51 (2002).
   PubMedGoogle Scholar
• Kempuraj D, Huang M, Kandere K et al. Azelastine is more potent than olopatadine in inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells. Ann. Allergy Asthma Immunol.88(5), 501–506 (2002).
   PubMed Web of Science ®Google Scholar
• Friedlander MH, Harris J, LaVallee N et al. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model. Ophthalmology107, 2152–2157 (2000).
   PubMed Web of Science ®Google Scholar
• Kamei C, Akagi M, Mio M et al. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (I). Elucidation of the mechanism for histamine release inhibition. Immunopharmacol. Immunotoxicol.14(1–2), 191–205 (1992).
   PubMed Web of Science ®Google Scholar
• Amon U, Gibbs BF, Buss G, Nitschke M. In vitro investigations with the histamine H1 receptor antagonist, epinastine (WAL 801 CL), on isolated human allergic effector cells. Inflamm. Res.49(3), 112–116 (2000).
   PubMed Web of Science ®Google Scholar
• Abelson MB, Gomes P, Crampton HJ, Schiffman RM, Bradford RR, Whitcup SM. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin. Ther.26(1), 35–47 (2004).
   PubMed Web of Science ®Google Scholar
• Whitcup SM, Bradford R, Lue J, Schiffman RM, Abelson MB. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. Clin. Ther.26(1), 29–34 (2004).
   PubMed Web of Science ®Google Scholar
• Schoch C. In vitro inhibition of human conjunctival mast-cell degranulation by ketotifen. J. Ocul. Pharmacol. Ther.19(1), 75–81 (2003).
   PubMed Web of Science ®Google Scholar
• Avunduk AM, Tekelioglu Y, Turk A, Akyol N. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clin. Ther.27(9), 1392–1402 (2005).
   PubMed Web of Science ®Google Scholar
• Kidd M, McKenzie SH, Steven I, Cooper C, Lanz R; Australian Ketotifen Study Group. Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. Br. J. Ophthalmol.87(10), 1206–1211 (2003).
   PubMed Web of Science ®Google Scholar
• Greiner JV, Mundorf T, Dubiner H et al. Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis. Am. J. Ophthalmol.136(6), 1097–1105 (2003).
   PubMed Web of Science ®Google Scholar
• Abelson MB, Ferzola NJ, McWhirter CL, Crampton HJ. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population. Pediatr. Allergy Immunol.15, 551–557 (2004).
   PubMed Web of Science ®Google Scholar
• Crampton HJ. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial. Clin. Ther.25(7), 1975–1987 (2003).
   PubMed Web of Science ®Google Scholar
• Hasala H, Malm-Erjefalt M, Erjefalt J et al. Ketotifen induces primary necrosis of human eosinophils. J. Ocul. Pharmacol. Ther.21(4), 318–327 (2005).
   PubMedGoogle Scholar
• Brockman HL, Momsen MM, Knudtson JR, Miller ST, Graff G, Yanni JM. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul. Immunol. Inflamm.11(4), 247–268 (2003).
   PubMed Web of Science ®Google Scholar
• Abelson MB. A review of olopatadine for the treatment of ocular allergy. Expert Opin. Pharmacother.5, 1979–1994 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenwasser LJ, O’Brien T, Weyne J. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of preclinical and clinical research. Curr. Med. Res. Opin.21(9), 1377–1387 (2005).
   PubMed Web of Science ®Google Scholar
• Leonardi A, Abelson MB. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin. Ther.25, 2539–2552 (2003).
   PubMed Web of Science ®Google Scholar
• Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann. Allergy Asthma Immunol.87(5), 424–429 (2001).
   PubMed Web of Science ®Google Scholar
• Cook EB, Stahl JL, Brooks AM, Graziano FM, Barney NP. Allergic tears promote upregulation of eosinophil adhesion to conjunctival epithelial cells in an ex vivo model: inhibition with olopatadine treatment. Invest. Ophthalmol. Vis Sci.47(8), 3423–3429 (2006).
   PubMedGoogle Scholar
• Cook EB, Stahl JL, Sedgwick JB, Barney NP, Graziano FM. The promotion of eosinophil degranulation and adhesion to conjunctival epithelial cells by IgE-activated conjunctival mast cells. Ann. Allergy Asthma Immunol.92(1), 65–67 (2004).
   PubMed Web of Science ®Google Scholar
• Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival allergen challenge model. Clin. Ther.22(7), 826–833 (2000).
   PubMed Web of Science ®Google Scholar
• Leonardi A, Zafirakis P. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference. Curr. Med. Res. Opin.20, 1167–1173 (2004).
   PubMed Web of Science ®Google Scholar
• Finegold I, Granet DB, D’Arienzo PA, Epstein AB. Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study. Clin. Ther.28(10), 1630–1638 (2006).
   PubMed Web of Science ®Google Scholar
• Berger W, Abelson MB, Gomes PJ et al. Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy. Ann. Allergy Asthma Immunol.95(4), 361–371 (2005).
   PubMed Web of Science ®Google Scholar
• Alexander M, Berger W, Buchholz P et al. The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ). Health Qual. Life Outcomes3, 67 (2005).
   PubMedGoogle Scholar
• Smith AF, Pitt AD, Rodruiguez AE et al. The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol.12(4), 233–242 (2005).
   PubMed Web of Science ®Google Scholar
• Frew AJ, Powell RJ, Corrigan CJ, Durham SR; UK Immunotherapy Study Group. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol.117(2), 319–325 (2006).
   PubMed Web of Science ®Google Scholar
• Ikeda H, Tsukamoto H, Sato E, Mishima HK, Kihira K. Daily cost of ophthalmic solutions used to treat allergic conjunctivitis in Japan. Ophthalmic Epidemiol.11, 35–42 (2004).
   PubMed Web of Science ®Google Scholar
• Pitt AD, Smith AF, Lindsell L, Voon LW, Rose PW, Bron AJ. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol.11, 17–33 (2004).
   PubMed Web of Science ®Google Scholar
• Guest JF, Clegg JP, Smith AF. Health economic impact of olopatadine compared to branded and generic sodium cromoglycate in the treatment of seasonal allergic conjunctivitis in the UK. Curr. Med. Res. Opin.22, 1777–1785 (2006).
   PubMed Web of Science ®Google Scholar
• Williams PB, Sheppard JD Jr. Omalizumab: a future innovation for treatment of severe ocular allergy? Expert Opin. Biol. Ther.5, 1603–1609 (2005).
   PubMed Web of Science ®Google Scholar
• Abelson MB, Gomes PJ, Vogelson CT et al. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis. Curr. Med. Res. Opin.21(5), 683–691 (2005).
   PubMed Web of Science ®Google Scholar
• Rivera J, Gilfillan AM. Molecular regulation of mast cell activation. J. Allergy Clin. Immunol.117, 1214–1225 (2006).
   PubMed Web of Science ®Google Scholar
• BenEzra D, Pe’er J, Brodsky M, Cohen E. Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis. Am. J. Ophthalmol.101, 278–282 (1986).
   PubMed Web of Science ®Google Scholar
• Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am. J. Ophthalmol.110, 137–142 (1990).
   Web of Science ®Google Scholar
• Pucci N, Novembre E, Cianferoni A et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann. Allergy Asthma Immunol.89, 298–303 (2002).
   PubMed Web of Science ®Google Scholar
• Hingorani M, Calder VL, Buckley RJ, Lightman S. The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci.40, 392–399 (1999).
   PubMed Web of Science ®Google Scholar
• Akpek EK, Dart JK, Watson S et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology.111, 476–482 (2004).
   PubMed Web of Science ®Google Scholar
• Daniell M, Constantinou M, Vu HT, Taylor HR. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br. J. Ophthalmol.90(4), 461–464 (2006).
   PubMed Web of Science ®Google Scholar
• Rikkers SM, Holland GN, Drayton GE, Michel FK, Torres MF, Takahashi S. Topical tacrolimus treatment of atopic eyelid disease. Am. J. Ophthalmol.135, 297–302 (2003).
   PubMed Web of Science ®Google Scholar
• Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P, Jirapongsananuruk O, Visitsunthorn N, Kosrirukvongs P. Vernal keratoconjunctivitis: result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment. J. Allergy Clin. Immunol.113, 355–358 (2004).
   PubMed Web of Science ®Google Scholar
• Virtanen HM, Reitamo S, Kari M, Kari O. Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. Acta Ophthalmol. Scand.84(5), 693–695 (2006).
   PubMedGoogle Scholar